Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Physiomics ( (GB:PYC) ) has shared an announcement.
Physiomics has urged shareholders to vote against resolutions proposed for a requisitioned general meeting on 29 April 2026, arguing that the activist-led bid to reshape the board is premature and could disrupt the company’s commercialisation strategy. Chairman Dr Jim Millen said the proposed directors lack the sector-specific scientific and operational expertise needed to monetise the firm’s IP and warned that abrupt changes without a credible transition plan risk undermining staff confidence, customer relationships and ongoing senior hires.
The board disclosed that it had offered substantial board representation, including two new non-executive directors and the right to recommend a further director, but talks collapsed over what it described as unusually high remuneration demands and unresolved governance issues. Physiomics also highlighted the withdrawal of a key proposed appointee with recent life sciences listed-company experience as evidence of inadequate preparation by the requisitioning group, and invited investors to an online presentation on 9 April 2026 to discuss the situation and address shareholder concerns, including over past dilution.
The most recent analyst rating on (GB:PYC) stock is a Sell with a £0.43 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Spark’s Take on PYC Stock
According to Spark, TipRanks’ AI Analyst, PYC is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and persistent cash burn), partially offset by a low-leverage balance sheet and some improvement in price trend. Valuation is constrained by negative earnings and lack of dividend support.
To see Spark’s full report on PYC stock, click here.
More about Physiomics
Physiomics plc is a specialist life sciences services company focused on drug development support through advanced mathematical modelling and biostatistics. Its core offerings include the Virtual Tumour platform and a personalised dosing tool in development, which underpin its consulting services and form key intellectual property aimed at pharmaceutical and biotech clients.
Average Trading Volume: 8,176,001
Technical Sentiment Signal: Sell
Current Market Cap: £2.06M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.